跳至主要内容
临床试验/CTRI/2010/091/000379
CTRI/2010/091/000379招募中4 期

A study to evaluate the effect of Lucentis® (Ranibizumab) on Vision Related Function using the VFQ-25 questionnaire in patients with wet age-related macular degeneration (AMD)

ovartis health care private limited0 个研究点目标入组 500 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
500

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Diagnosed with choroidal neovascularization (CNV) secondary to (wet) AMD
  • 2.Willing to provide informed consent (as per the local practices)
  • Patients may have received Lucentis monotherapy or combination therapy [with Visudyne® (verteporfin)]

排除标准

  • 1.Hypersensitivity to the active substance or to any of the excipients.
  • 2.Patients with active or suspected ocular or periocular infections.
  • 3.Patients with active intraocular inflammation.

研究者

发起方
ovartis health care private limited

相似试验